Discovery of circulating microRNAs associated with human prostate cancer using a mouse model of disease

International Journal of Cancer

Volumn 131, Issue 3, 2012, Pages 652-661

  Selth, Luke A ^a   Townley, Scott ^a   Gillis, Joanna L ^a   Ochnik, Aleksandra M ^a   Murti, Krisna ^a   Macfarlane, Robyn J ^c   Chi, Kim N ^b,c   Marshall, Villis R ^a   Tilley, Wayne D ^a   Butler, Lisa M ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

biomarker; microRNA; mouse model; prostate cancer; serum

Indexed keywords

DOCETAXEL; MICRORNA; MICRORNA 141; MICRORNA 298; MICRORNA 346; MICRORNA 375; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BLOOD LEVEL; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; LIVER METASTASIS; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; RNA ANALYSIS; UPREGULATION; VALIDATION PROCESS;

ANIMALS; GENE EXPRESSION PROFILING; HUMANS; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84861538794     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26405     Document Type: Review

References (44)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P,. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18: 581-92.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
3. Kohli M, Tindall DJ,. New developments in the medical management of prostate cancer. Mayo Clin Proc 2010; 85: 77-86.
4. Nwosu V, Carpten J, Trent JM, Sheridan R,. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet 2001; 10: 2313-8.
5. Rajan P, Elliott DJ, Robson CN, Leung HY,. Alternative splicing and biological heterogeneity in prostate cancer. Nat Rev Urol 2009; 6: 454-60.
6. Friedman RC, Farh KK, Burge CB, Bartel DP,. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
7. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
8. Di Leva G, Croce CM,. Roles of small RNAs in tumor formation. Trends Mol Med 2010; 16: 257-67.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
10. Tam W,. The emergent role of microRNAs in molecular diagnostics of cancer. J Mol Diagn 2008; 10: 411-4.
11. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008; 105: 10513-8.
12. Xi Y, Nakajima G, Gavin E, Morris CG, Kudo K, Hayashi K, Ju J,. Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 2007; 13: 1668-74.
13. Steuber T, O'Brien MF, Lilja H,. Serum markers for prostate cancer: a rational approach to the literature. Eur Urol 2008; 54: 31-40.
14. Lawrie CH, Gal S, Dunlop HM, Pushkaran B, Liggins AP, Pulford K, Banham AH, Pezzella F, Boultwood J, Wainscoat JS, Hatton CS, Harris AL,. Detection of elevated levels of tumor-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol 2008; 141: 672-5.
15. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008; 18: 997-1006.
16. Liu R, Zhang C, Hu Z, Li G, Wang C, Yang C, Huang D, Chen X, Zhang H, Zhuang R, Deng T, Liu H, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 2010; 47: 784-91.
17. Lodes MJ, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B,. Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One 2009; 4: e6229.
18. Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H,. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 2010; 128: 608-16.
19. Zhang HL, Yang LF, Zhu Y, Yao XD, Zhang SL, Dai B, Zhu YP, Shen YJ, Shi GH, Ye DW,. Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy. Prostate 2010; 71: 326-31.
20. Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stoppler H, Simko J, Hilton JF, Carroll P, Blelloch R,. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Res 2011; 71: 550-60.
21. Kuick R, Misek DE, Monsma DJ, Webb CP, Wang H, Peterson KJ, Pisano M, Omenn GS, Hanash SM,. Discovery of cancer biomarkers through the use of mouse models. Cancer Lett 2007; 249: 40-8.
22. Gingrich JR, Barrios RJ, Foster BA, Greenberg NM,. Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prostate Cancer Prostatic Dis 1999; 2: 70-5.
23. Faca VM, Song KS, Wang H, Zhang Q, Krasnoselsky AL, Newcomb LF, Plentz RR, Gurumurthy S, Redston MS, Pitteri SJ, Pereira-Faca SR, Ireton RC, et al. A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 2008; 5: e123.
24. Pitteri SJ, Faca VM, Kelly-Spratt KS, Kasarda AE, Wang H, Zhang Q, Newcomb L, Krasnoselsky A, Paczesny S, Choi G, Fitzgibbon M, McIntosh MW, et al. Plasma proteome profiling of a mouse model of breast cancer identifies a set of up-regulated proteins in common with human breast cancer cells. J Proteome Res 2008; 7: 1481-9.
25. Gingrich JR, Barrios RJ, Morton RA, Boyce BF, DeMayo FJ, Finegold MJ, Angelopoulou R, Rosen JM, Greenberg NM,. Metastatic prostate cancer in a transgenic mouse. Cancer Res 1996; 56: 4096-102.
26. Chiaverotti T, Couto SS, Donjacour A, Mao JH, Nagase H, Cardiff RD, Cunha GR, Balmain A,. Dissociation of epithelial and neuroendocrine carcinoma lineages in the transgenic adenocarcinoma of mouse prostate model of prostate cancer. Am J Pathol 2008; 172: 236-46.
27. Kroh EM, Parkin RK, Mitchell PS, Tewari M,. Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR). Methods 2010; 50: 298-301.
28. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010; 18: 11-22.
29. Lopez-Romero P,. Pre-processing and differential expression analysis of Agilent microRNA arrays using the AgiMicroRna Bioconductor library. BMC Genomics 2011; 12: 64.
30. Carmona-Saez P, Chagoyen M, Tirado F, Carazo JM, Pascual-Montano A,. GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists. Genome Biol 2007; 8: R3.
31. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T,. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 2009; 37: D105-10.
32. Robinson DR, Zylstra CR, Williams BO,. Wnt signaling and prostate cancer. Curr Drug Targets 2008; 9: 571-80.
33. El Sheikh SS, Domin J, Abel P, Stamp G, Lalani el N,. Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalk. Neoplasia 2003; 5: 99-109.
34. Jones E, Pu H, Kyprianou N,. Targeting TGF-beta in prostate cancer: therapeutic possibilities during tumor progression. Expert Opin Ther Targets 2009; 13: 227-34.
35. Kela I, Harmelin A, Waks T, Orr-Urtreger A, Domany E, Eshhar Z,. Interspecies comparison of prostate cancer gene-expression profiles reveals genes associated with aggressive tumors. Prostate 2009; 69: 1034-44.
36. Artzi S, Kiezun A, Shomron N,. miRNAminer: a tool for homologous microRNA gene search. BMC Bioinformatics 2008; 9: 39.
37. Boissonneault V, Plante I, Rivest S, Provost P,. MicroRNA-298 and microRNA-328 regulate expression of mouse beta-amyloid precursor protein-converting enzyme 1. J Biol Chem 2009; 284: 1971-81.
38. Provost P,. Interpretation and applicability of microRNA data to the context of Alzheimer's and age-related diseases. Aging 2010; 2: 166-9.
39. Oskowitz AZ, Lu J, Penfornis P, Ylostalo J, McBride J, Flemington EK, Prockop DJ, Pochampally R,. Human multipotent stromal cells from bone marrow and microRNA: regulation of differentiation and leukemia inhibitory factor expression. Proc Natl Acad Sci USA 2008; 105: 18372-7.
40. Wach S, Nolte E, Szczyrba J, Stohr R, Hartmann A, Orntoft T, Dyrskjot L, Eltze E, Wieland W, Keck B, Ekici AB, Grasser F, et al. MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer 2011.
41. Waltering KK, Porkka KP, Jalava SE, Urbanucci A, Kohonen PJ, Latonen LM, Kallioniemi OP, Jenster G, Visakorpi T,. Androgen regulation of micro-RNAs in prostate cancer. Prostate 2010; 71: 604-14.
42. Kuwabara Y, Ono K, Horie T, Nishi H, Nagao K, Kinoshita M, Watanabe S, Baba O, Kojima Y, Shizuta S, Imai M, Tamura T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate the existence of myocardial damage. Circ Cardiovasc Genet 2011.
43. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, Pfeffer S, Tuschl T, Rajewsky N, Rorsman P, Stoffel M,. A pancreatic islet-specific microRNA regulates insulin secretion. Nature 2004; 432: 226-30.
44. Evans MK, Yu CR, Lohani A, Mahdi RM, Liu X, Trzeciak AR, Egwuagu CE,. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 2007; 26: 1941-8.